TAPI-1 is a TACE (ADAM17) inhibitor and blocks the shedding of several cell surface proteins. TAPI-1 is also a metalloproteinase (MMP) inhibitor.
性状
Solid
IC50 & Target[1][2]
TACE (ADAM17), MMP
体外研究(In Vitro)
TAPI-1 (1 μM for 30 min) increases cell viability in LPS-treated HK-2 cells.TAPI-1 attenuates oxidative stress and inflammatory cytokinesLPS treatment significantly induces renal IL-6 and TNFα mRNA expression, while these changes is attenuated with TAPI-1 pretreatment in LPS-treated HK-2 cells. has not independently confirmed the accuracy of these methods. They are for reference only.Cell Viability Assay
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Bae EH, et al. Tumor necrosis factor α-converting enzyme inhibitor attenuates lipopolysaccharide-induced reactive oxygen species and mitogen-activated protein kinase expression in human renal proximal tubule epithelial cells. Korean J Physiol Pharmacol. 2[2]. Moss ML, et al. Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. Mediators Inflamm. 2017;2017:9673537.